Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Published on :

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of three new executive leaders including Scott Greenberg as Chief Operating Officer, Jeffrey Staiger as Senior Vice President of Finance and Business Development, and Michael Tortorici, PharmD, Ph.D. as Vice President of Clinical Pharmacology and Non-Clinical Development. Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team. The Company also announced plans to move its headquarters to The Curtis in Philadelphia to accommodate ongoing growth of its operations and staff.

Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021

Published on :

Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 PHILADELPHIA (April 8, 2021) – The robust venture capital funding the Greater [….]

10 Philadelphia Biotech Companies Targeting Rare Diseases

Published on :

Philadelphia, the birthplace of cell and gene therapy, is home to a number of companies focused on developing multiple treatment options for rare diseases, those that affect less than 200,000 people in the United States.